Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Mind Medicine Sees FDA Place Clinical Hold On Phase 2b Study
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(800)
•••
Comment by SouthernTierTomon Dec 29, 2021 9:55pm
269 Views
Post# 34269621

RE:RE:Mind Medicine Sees FDA Place Clinical Hold On Phase 2b Study

RE:RE:Mind Medicine Sees FDA Place Clinical Hold On Phase 2b StudyYou mentioned "paid jerk"?

I thought the press release stated that this in fact did happen?

Is this incorrect?

Do you think it will trend back up towards that 3 BILLION CAD valuation once they "sort it out"?

I find your repsonse to "apparent fact" curious and somewhat troublesome...are you OK fella?

I feel badly for those that paid $7 CAD on the back of an ~ 3 BILLION CAD valuation..

How did that happen? ... I guess the good news is that it is still valued at 840M CAD...

So they would ask for 8.4M for 1% of our company? Hmmmm seems steep...no?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities